Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
- PMDA Reviewing Anaphylaxis Risk for Xocova
June 29, 2023
- MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
- After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
June 28, 2023
- SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
June 28, 2023
- Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
- Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
June 27, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
- Japan Reports World’s 1st Death from Oz Virus
June 26, 2023
- PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
June 26, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- Avigan, 3 Other Drugs Get Orphan Status in Japan
June 23, 2023
- Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
- Chuikyo OKs Drug Price Survey Plan for FY2024 Revision
June 22, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- MHLW Panel Discusses 6 Risks to Drug Supplies; Need for Industry Consolidation Raised
June 21, 2023
- MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
- Ryukaikon to Meet June 26 to Discuss Expert Panel Proposals
June 21, 2023
- MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…